Abbisko and Sperogenix Partner to Develop ABSK021 for ALS, Other Rare CNS Diseases in Greater China globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Abbisko and Sperogenix Announce An Exclusive Agreement to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China
July 5, 2021 GMT
SHANGHAI, BEIJING, HONG KONG, July 4, 2021 /PRNewswire/ Sperogenix (Shanghai) MedTech Co., Ltd. (“Sperogenix”), a subsidiary of Sperogenix Therapeutics (platform company for development and commercialization of rare diseases medications in China), has entered into an exclusive licensing agreement with Abbisko Therapeutics Co., Ltd. (“Abbisko”), a Chinese biopharmaceutical company focused on innovative drug discovery and development, to collaborate on the development and commercialization of innovative drug ABSK021 for indications in the field of rare neurological diseases.